Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Stock Information for Relmada Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Relmada Therapeutics Inc.

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
ORAGENICS PROVIDES INVESTOR UPDATE
Oragenics Signs Letter of Intent to License CardioDialysis(TM) Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.